Medication info

Bilitin Tablet 50 mg (Vildagliptin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
Pharmgen Science Co., Ltd.
Appearance
White to light yellow round tablets
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202102216 · Approved 2021.03.10

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For monotherapy, or when used in combination with metformin in patients with no prior experience of antidiabetic drug therapy, this medicine is administered at 50mg once daily in the morning or at 100mg daily, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or a thiazolidinedione as monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg daily, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with a sulfonylurea as monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is used in combination (as triple therapy) is 100mg daily, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is used in combination is 100mg daily, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses above 100mg daily are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Patients with renal impairment Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 3, General Precautions, item 2, under Precautions for Use.)

Ingredients

Manufacturer
Pharmgen Science Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes in conjunction with diet and exercise. It can be initiated as monotherapy, and if previous pharmacologic therapy has not been experienced and controlling blood sugar alone is difficult, it can be used in combination with metformin. This medication is also used in combination with sulfonylureas, metformin, or thiazolidinediones when blood sugar control is not sufficient with monotherapy. If blood sugar control remains difficult after combination therapy with sulfonylureas and metformin, this medication is additionally administered. It can also be used in combination when blood sugar control is inadequate after insulin therapy alone or with metformin. It is used effectively to improve blood sugar control in this wide variety of situations.

How to take

Adult dose

For monotherapy, or when used in combination with metformin in patients with no prior experience of antidiabetic drug therapy, this medicine is administered at 50mg once daily in the morning or at 100mg daily, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or a thiazolidinedione as monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg daily, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with a sulfonylurea as monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is used in combination (as triple therapy) is 100mg daily, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is used in combination is 100mg daily, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses above 100mg daily are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Patients with renal impairment Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 3, General Precautions, item 2, under Precautions for Use.)

Precautions

This medication should not be used in patients with known allergic reactions to the active ingredient or other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Additionally, patients with lactose intolerance or specific genetic metabolic disorders should not take this medication. Liver function abnormalities can occur rarely during use of this medication; therefore, regular liver function tests should be conducted. If liver function levels significantly rise or symptoms of jaundice appear, the medication should be discontinued immediately. This medication is not recommended for patients with heart failure, particularly those with severe heart failure. Due to the risk of acute pancreatitis, if symptoms of pancreatitis occurring include abdominal pain or vomiting, a physician should be consulted immediately. There is a risk of hypoglycemia; therefore, dose adjustments may be needed when taken with insulin secretagogues. If symptoms such as dizziness occur, it is advisable to avoid driving or operating machinery. Severe joint pain or skin lesions such as blisters or ulcers should be reported to healthcare professionals promptly. Pregnant or nursing women should not use this medication, and it is also not recommended for children or adolescents under 18 years of age. In case of overdose, there is no specific antidote; therefore, appropriate supportive treatment is necessary based on symptoms. Keep out of reach of children and do not transfer to other containers for safety.

Side effects

  • Hepatitis
  • liver dysfunction
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
Show 52 more
  • pharyngitis
  • asthenia
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • abdominal distension
  • chills
  • decreased blood sugar
  • sweating
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and disabling arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • upper respiratory infection
  • chest discomfort
  • dyspnea
  • acute myocardial infarction
  • cough
  • dyspepsia
  • drowsiness
  • vertigo
  • pruritus
  • dry mouth
  • vomiting
  • insomnia
  • kidney impairment
  • lip blisters
  • hunger
  • sensory loss
  • spinal canal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • appendicitis
  • fatty liver
  • hyperkalemia
  • hypertriglyceridemia
  • heart failure
  • left ventricular hypertrophy
  • angina
  • cardiac arrest
  • renal cyst
  • lung cancer
  • leg pain
  • increased C-reactive protein

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

White to light yellow round tablets

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.